Holen Sie sich die Stockscreener-App
135.44
2.12%
-2.93
Handel nachbörslich:
135.44
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt A?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$138.37
Offen:
$137.95
24-Stunden-Volumen:
2.18M
Relative Volume:
0.98
Marktkapitalisierung:
$38.25B
Einnahmen:
$7.23B
Nettoeinkommen (Verlust:
$1.41B
KGV:
27.20
EPS:
4.979
Netto-Cashflow:
$1.09B
1W Leistung:
-0.07%
1M Leistung:
+15.24%
6M Leistung:
-6.91%
1J Leistung:
+18.87%
1-Tages-Spanne:
$134.91
$139.00
1-Wochen-Bereich:
$132.13
$141.09
52-Wochen-Spanne:
$108.35
$160.27
Agilent Technologies Inc Stock (A) Company Profile
Firmenname
Agilent Technologies Inc
Sektor
Branche
Telefon
(408) 345-8886
Adresse
5301 STEVENS CREEK BLVD, SANTA CLARA, CA
Compare A vs TMO, DHR, IDXX, WAT
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
A
Agilent Technologies Inc
|
135.44 | 39.08B | 7.23B | 1.41B | 1.09B | 4.979 |
TMO
Thermo Fisher Scientific Inc
|
472.80 | 179.13B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
184.30 | 132.10B | 24.78B | 3.68B | 5.29B | 5.1743 |
IDXX
Idexx Laboratories Inc
|
562.16 | 44.55B | 4.45B | 1.10B | 1.06B | 13.59 |
WAT
Waters Corp
|
365.36 | 36.96B | 3.77B | 449.25M | 240.68M | 7.8556 |
Agilent Technologies Inc Stock (A) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-20 | Eingeleitet | HSBC Securities | Buy |
| 2026-01-05 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2025-12-15 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2025-12-09 | Eingeleitet | Goldman | Buy |
| 2025-12-02 | Eingeleitet | Morgan Stanley | Overweight |
| 2025-10-08 | Eingeleitet | Rothschild & Co Redburn | Buy |
| 2025-10-08 | Hochstufung | UBS | Neutral → Buy |
| 2025-02-10 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-08-28 | Eingeleitet | Wells Fargo | Overweight |
| 2024-07-10 | Hochstufung | Citigroup | Neutral → Buy |
| 2024-06-27 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2024-06-03 | Fortgesetzt | Jefferies | Hold |
| 2024-04-05 | Hochstufung | Stifel | Hold → Buy |
| 2023-12-13 | Eingeleitet | Wolfe Research | Outperform |
| 2023-12-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-11-17 | Herabstufung | UBS | Buy → Neutral |
| 2023-09-28 | Eingeleitet | Bernstein | Mkt Perform |
| 2023-07-31 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2023-05-24 | Bestätigt | Barclays | Equal Weight |
| 2023-05-24 | Bestätigt | BofA Securities | Buy |
| 2023-05-24 | Bestätigt | Citigroup | Neutral |
| 2023-05-24 | Bestätigt | Credit Suisse | Outperform |
| 2023-05-24 | Bestätigt | Evercore ISI | Outperform |
| 2023-05-24 | Herabstufung | KeyBanc Capital Markets | Overweight → Sector Weight |
| 2023-05-24 | Bestätigt | Robert W. Baird | Outperform |
| 2023-05-24 | Bestätigt | SVB Securities | Outperform |
| 2023-05-24 | Bestätigt | Stifel | Hold |
| 2023-05-24 | Bestätigt | TD Cowen | Outperform |
| 2023-05-24 | Bestätigt | Wells Fargo | Overweight |
| 2023-05-11 | Eingeleitet | Barclays | Equal Weight |
| 2023-01-10 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-08-25 | Eingeleitet | Credit Suisse | Outperform |
| 2022-07-20 | Eingeleitet | UBS | Buy |
| 2022-07-08 | Herabstufung | Citigroup | Buy → Neutral |
| 2022-04-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2022-02-23 | Bestätigt | BofA Securities | Buy |
| 2022-02-23 | Bestätigt | Citigroup | Buy |
| 2022-02-23 | Bestätigt | Cowen | Outperform |
| 2022-02-23 | Bestätigt | Evercore ISI | Outperform |
| 2022-02-23 | Bestätigt | Stifel | Hold |
| 2022-02-23 | Bestätigt | Wells Fargo | Overweight |
| 2021-11-23 | Bestätigt | BofA Securities | Buy |
| 2021-11-23 | Bestätigt | Cowen | Outperform |
| 2021-11-23 | Bestätigt | Stifel | Hold |
| 2021-03-18 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-02-17 | Hochstufung | BofA Securities | Neutral → Buy |
| 2020-12-02 | Eingeleitet | Goldman | Buy |
| 2020-11-25 | Hochstufung | UBS | Neutral → Buy |
| 2020-11-17 | Hochstufung | Cleveland Research | Neutral → Buy |
| 2020-11-10 | Eingeleitet | KeyBanc Capital Markets | Overweight |
| 2020-09-30 | Eingeleitet | Atlantic Equities | Neutral |
| 2020-08-19 | Bestätigt | BofA Securities | Neutral |
| 2020-08-19 | Bestätigt | Citigroup | Neutral |
| 2020-08-19 | Bestätigt | Jefferies | Buy |
| 2020-08-19 | Bestätigt | Robert W. Baird | Outperform |
| 2020-08-19 | Bestätigt | SVB Leerink | Outperform |
| 2020-08-19 | Bestätigt | Stifel | Hold |
| 2020-08-19 | Bestätigt | Wells Fargo | Overweight |
| 2020-02-24 | Herabstufung | Needham | Buy → Hold |
| 2020-01-08 | Eingeleitet | Wells Fargo | Overweight |
| 2020-01-07 | Eingeleitet | Citigroup | Neutral |
| 2019-11-26 | Bestätigt | Needham | Buy |
| 2019-11-15 | Eingeleitet | Stifel | Hold |
| 2019-10-18 | Herabstufung | UBS | Buy → Neutral |
| 2019-07-16 | Herabstufung | BofA/Merrill | Buy → Neutral |
| 2019-07-15 | Herabstufung | Barclays | Overweight → Equal Weight |
Alle ansehen
Agilent Technologies Inc Aktie (A) Neueste Nachrichten
Return on invested capital % of Agilent Technologies, Inc. – XETR:AG8 - TradingView
Inventory turnover of Agilent Technologies, Inc. – XETR:AG8 - TradingView
TRADE NEWS: Agilent Technologies Announces Enhancements to Automate Verizon IMS VoIP Compliance Test - AOL.com
Agilent (NYSE: A) VP reports 8,872 share holding and RSU grant - Stock Titan
Agilent (NYSE: A) CEO surrenders 418 shares to cover RSU tax liability - Stock Titan
Agilent Q2 earnings call shows Ignite driving a higher outlook - MSN
Agilent introduces the 9500 Triple Quadrupole ICP-MS – Redefining trace element analysis - Select Science
Agilent stock is having its best day since 2002. Earnings leave Wall Street with ‘little to pick at.’ - MSN
A Look At Agilent Technologies (A) Valuation As FDA Approval AI Deal And Earnings Update Draw Focus - simplywall.st
Agilent Technologies (A) Is Up 18.6% After AI Pact With OpenAI And Raised 2026 GuidanceHas The Bull Case Changed? - Yahoo Finance
Agilent lands $9M TSA contract for next-gen airport screening tech - Delaware Business Times
$Agilent Technologies (A.US)$ - Moomoo
Agilent Technologies, Inc. Trade Ideas — XETR:AG8 - TradingView
Agilent Technologies Inc. stock (US00846U1016): shares firm after May earnings as life-science deman - AD HOC NEWS
Agilent presents its integrated mass spectrometry and chromatography solutions at ASMS 2026 - SelectScience
Agilent Technologies Inc. stock outperforms competitors on strong trading day - MarketWatch
Why Agilent Technologies stock triumphed on Thursday - MSN
Agilent partners with OpenAI and BCG to embed AI across scientific instruments and operations - The Business Journals
Agilent Technologies Inc. stock (US00846U1016): Insider share sale follows FDA approval and guidance - AD HOC NEWS
HSBC Maintains Agilent Technologies(A.US) With Buy Rating, Cuts Target Price to $165 - Moomoo
HSBC Adjusts Price Target on Agilent Technologies to $165 From $180, Maintains Buy Rating - Moomoo
Agilent Technologies (A) Declined in Q1 Amid QIAGEN Acquisition Speculation - Insider Monkey
Agilent rises on Q2 beats; adjusts fiscal 2026 guidance - MSN
Agilent Technologies Partners With OpenAI, Boston Consulting for AI Deployment - Moomoo
Agilent partners with OpenAI and BCG to deploy AI solutions By Investing.com - Investing.com South Africa
Agilent partners with OpenAI and BCG to deploy AI solutions - Investing.com
Agilent, OpenAI, BCG Collaborate to Accelerate Customer-Focused, AI-Driven Scientific Innovation - The Joplin Globe
OpenAI joins Agilent lab tools in new push to speed up scientific discovery - Stock Titan
A SWOT Analysis: Agilent Technologies Inc (A) Shows Strong Growt - GuruFocus
Agilent upgraded at BofA on FQ2 beats, growth - MSN
FDA approves Agilent’s PD-L1 test expansion for four cancers By Investing.com - Investing.com Nigeria
Agilent Gets US FDA Clearance for Expanded Use of Cancer Test on Dako Omnis Platform - Moomoo
FDA approves Agilent’s PD-L1 test expansion for four cancers - Investing.com
FDA broadens cancer test to find more patients eligible for Keytruda - Stock Titan
Agilent (NYSE: A) director trims stake with 1,600-share stock sale - Stock Titan
Agilent Technologies Stock On Fire: Up 20% With 8-Day Winning Streak - Trefis
BofA Securities Adjusts Agilent Technologies PT to $155 From $145 - marketscreener.com
Is Now The Time To Look At Buying Agilent Technologies, Inc. (NYSE:A)? - Yahoo Finance
Agilent Technologies Q2 2026 Financial Report – Earnings, Revenue, and SEC Filing Highlights - Minichart
Agilent Technologies Inc. stock (US00846U1016): shares advance after stronger Q2 2026 results and hi - AD HOC NEWS
Agilent Technologies : and Sound Analytics Collaborate to Advance LC/MS Workflows for Drug Metabolism Research - marketscreener.com
Agilent Technologies 2Q 2026: Revenue $1.84B, EPS $1.2— 10-Q Summary - TradingView
Agilent (NYSE: A) posts profit growth, $950M Biocare deal and strong cash - Stock Titan
Jim Cramer on Agilent: “There Might Be an Opportunity” - Insider Monkey
Agilent Technologies Inc. stock (US00846U1016): shares in focus after recent earnings and analyst up - AD HOC NEWS
Agilent (A) Reliance on International Sales: What Investors Need to Know - Yahoo Finance
Agilent Technologies (A) Is Up 17.9% After Raising 2026 Outlook And Expanding Lab Informatics Portfolio - simplywall.st
Agilent launches new GC Systems to improve laboratory efficiency and data quality - BioSpectrum India
Agilent Q2 Earnings Call Shows Ignite Driving a Higher Outlook - TradingView
Agilent Technologies, Inc. (A) Stock Analysis: Strong Buy Ratings and 19% Potential Upside Drive Investor Interest - DirectorsTalk Interviews
Agilent Technologies Opens with 16.54% Gain, Outperforming S&P 500's 0.58% Rise - Markets Mojo
Finanzdaten der Agilent Technologies Inc-Aktie (A)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.95%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):